Navigation Links
Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
Date:3/1/2010

FREMONT, Calif., March 1 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.  This drug candidate, having a proprietary siRNA structure, is being developed for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).  The current trial represents the seventh clinical study of Quark synthetic siRNAs.  QPI-1007 has been evaluated in several preclinical models of ocular neuroprotection, and has been shown in these models to protect retinal ganglion cells from injury-induced apoptosis.

The study is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug will be given to all patients who participate.  This study will determine whether QPI-1007 is safe when it is injected into the eye and will also reveal if there are any side effects of the drug and how long it takes for the body to clear the drug.  In addition, the study will examine the biological activity of the drug in NAION patients.  The study will enroll patients in two strata, and is being conducted in the U.S. and Israel.  Stratum I will enroll legally blind patients, while stratum II will enroll patients with recent onset of NAION.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
2. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
3. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
4. Quark Pharmaceuticals Presents at Asia TIDES Conference
5. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
6. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
7. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014   TRU-D SmartUVC LLC, ... disinfection robot, announced today that the General Services Administration ... November 2019.   This newly formed agreement ... levels of government purchasers, including Department of Veteran Affairs ... Homeland Security contacts purchasing solutions for the Ebola effort ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a global leader ... today announced it will participate in the 33 rd ... in San Francisco . ... speak at 11:00 AM Pacific Time.  A live audio webcast ... Investor Relations link on the Cyberonics home page at ...
(Date:12/22/2014)... Dec. 22, 2014  Mark Farrah Associates (MFA), ... a summary of the 2015 marketplace exchange projections ... According to a recent ASPE ... Evaluation, Department of Health and Human Services) report, ... individual medical plans through the Marketplace as of ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Insights into the Marketplace and Individual Market Growth 2
... Inc. announced today that it has completed notifying customers ... ventilators in the United States and has confirmed that ... was initiated on October 11, 2011 to address a ... received no reports of ventilator malfunctions, failures or injuries ...
... 12, 2012 The Federal Trade Commission (FTC) announced ... to settle allegations that the company overcharged seniors and ... the FTC has concluded its investigation into charges alleging ... following the 2007 merger of mega-chain CVS with pharmacy ...
Cached Medicine Technology:Respironics, Inc. Completes Voluntary Recall Notification of a Limited Number of Trilogy 100 Ventilators 2NCPA Comments on FTC Action Against CVS Caremark, Vows to Continue PBM Transparency Efforts 2NCPA Comments on FTC Action Against CVS Caremark, Vows to Continue PBM Transparency Efforts 3
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
(Date:12/25/2014)... When head lice hits a home or school, parents and ... of it while keeping it from taking over the house ... solution right in their neighborhood: Lice Troopers . Expanding ... spectrum head lice screening and treatment services to families and ... Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , The ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... into lakes and rivers from municipal sewage treatment plants ... bacteria antibiotic-resistant. That,s the conclusion of a new study ... the Duluth, Minn., harbor that appears in ACS, journal ... LaPara and colleagues explain that antibiotic-resistant bacteria a ...
... WEDNESDAY, Dec. 7 (HealthDay News) -- Two U.S. Food and ... to recommend new warning labels about increased risk of blood ... Reproductive Health Drugs Advisory Committee and the Drug Safety and ... public, and then make a recommendation to the full FDA. ...
... a novel therapeutic approach to treating breast cancer, Loyola University ... trial of a drug that targets tumor stem cells., Existing ... a handful of cancer stem cells are resistant to such ... tumor cells., A pilot study at Loyola found that an ...
... A majority of Americans professing belief in God favor ... spread of nuclear weapons - branding it a moral ... jointly by the University of Maryland,s Center for International ... on International Policy Attitudes (PIPA). The nearly 1,500 ...
... Ill. -- Changing the order in which two drugs are ... cancer, a study has found., Women who took the drugs ... longer than women who took the drugs in sequence, researchers ... Cancer Symposium., "This most likely will change the standard of ...
... recognize the following scenario: Their favorite player scores a three-point ... ball. But does the fact that he scored the last ... it change the probability that he will score again? ... Neiman at the Hebrew University in Jerusalem shatters the myth ...
Cached Medicine News:Health News:FDA Panels to Weigh Safety of Newer Forms of the 'Pill' 2Health News:FDA Panels to Weigh Safety of Newer Forms of the 'Pill' 3Health News:Novel approach to treating breast cancer shows great promise 2Health News:US believers favor international action on climate change, nuclear risk: UMD poll 2Health News:US believers favor international action on climate change, nuclear risk: UMD poll 3Health News:Changing order drugs are taken boosts breast cancer survival 2Health News:Heads up Kobe Bryant! Research shows that trying for another 3-pointer is a mistake 2
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Extra Security with porous tape....
Built-in convexity means added security and skin protection for recessed, retracted and flush stomas...pre-cut openings. Security and confidence achieved by the internal No-Flowback Valves and soft d...
Protects the skin over extended wearing time from irritating discharge. Flextend skin barrier is the barrier of choice for urostomies and ileostomies with the added benefit of it being discreet in bo...
Inquire...
Medicine Products: